Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
Abdullah Kutlar, MD
Sickle Cell Center of Excellence
1120 15th Street
Augusta, Georgia, United States
Dr. Kutlar has served Augusta University since 1982 where he has made major contributions to clinical care, basic science, clinical research, and educational activities. He is a graduate of Ankara University Medical School in Ankara, Turkey. He completed his residency and one year as chief resident and fellowship in internal medicine/hematology at Istanbul University Medical School in Istanbul, Turkey.
Following clinical and research fellowships in Turkey, a Special Fellow in the Department of Laboratory Hematology at the Cleveland Clinic in Cleveland, and as a Research Fellow at the Medical College of Georgia, he joined the faculty at the Medical College of Georgia as an Associate Professor in 1992. Dr. Kutlar practices hematology with a focus on benign hematology and is an active member of the American Society of Hematology. He has served and continues to serve on state and NIH committees.
Dr. Kutlar is currently the Co-PD/PI of the multi-institutional National Institute of Minority Health and Health Disparities Southeastern Exploratory Sickle Cell Center of Excellence as well as the Co-PD/PI of the National Heart, Lung, and Blood Institute’s Excellence in Hemoglobinopathies Research Award. He has completed more than 20 industry sponsored trials and federally funded projects, is working on two investigator initiated projects, and has brought to Augusta University an excess of nine million dollars in research support. Dr. Kutlar has 200 original articles, two book chapters, and 177 abstract presentations.
Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial
Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043)
Opioid Abuse Backlash Could Hurt Sickle Cell Patients’ Medication Needs, Some FearWith drug overdoses now the leading caus...
NewYork-Presbyterian Brooklyn Methodist HospitalThe Sickle Cell/Thalassemia Program at N...
Johns Hopkins Berman Institute of BioethicsEstablished in 1995, the Berman Institut...
Patrick C. Hines, MD, PhDPatrick C. Hines, MD, PhD is an experien...
Emergency Department Utilization for Patients Living With Sickle Cell Disease: Psychosocial Predictors of Health Car...Study objective: Individuals living wit...
Marsha Treadwell, PhDMarsha J. Treadwell, PhD, is a clinical ...
Use of telemedicine to improve access to clinical services and treatment for children with sickle cell diseasePatients with sickle cell disease (SCD) ...